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Abstract
Peptide vaccination in cancer therapy is a promising alternative to conventional methods. However, the parameters for this
personalized treatment are difficult to access experimentally. In this respect, in silico models can help to narrow down the
parameter space or to explain certain phenomena at a systems level. Herein, we develop two empirical interaction
potentials specific to B-cell and T-cell receptor complexes and validate their applicability in comparison to a more general
potential. The interaction potentials are applied to the model VaccImm which simulates the immune response against solid
tumors under peptide vaccination therapy. This multi-agent system is derived from another immune system simulator (C-
ImmSim) and now includes a module that enables the amino acid sequence of immune receptors and their ligands to be
taken into account. The multi-agent approach is combined with approved methods for prediction of major
histocompatibility complex (MHC)-binding peptides and the newly developed interaction potentials. In the analysis, we
critically assess the impact of the different modules on the simulation with VaccImm and how they influence each other. In
addition, we explore the reasons for failures in inducing an immune response by examining the activation states of the
immune cell populations in detail. In summary, the present work introduces immune-specific interaction potentials and
their application to the agent-based model VaccImm which simulates peptide vaccination in cancer therapy.
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Introduction
Cancer is still one of the major causes of death in industrial
nations, although in principle the immune system is able to
eradicate a tumor. Bearing that in mind, many studies have tried
to trigger an anticancer immune response using different methods,
e.g. adoptive cell transfer, cytokine therapy or vaccination
schedules [1]. Immune therapy is promising, but its success has
been limited so far. The main reason is that the mechanisms of the
tumor-immune-interplay are still poorly understood. A huge
amount of, sometimes conflicting, data has accumulated, which
can be difficult to interpret. Therefore, it is desirable to have a
simplified model able to highlight at the system level the main
processes of the phenomenon. In addition, in silico experiments are
far less expensive, less time consuming and a lot more flexible in
terms of parameter changes.
We have described the main theoretical modeling techniques,
differential equations and rule-based models, and their application
to tumor immunology elsewhere [2]. For this project, we have
chosen a rule-based model because of its capability to characterize
every single cell or molecule in its location, developmental state
and specificity.
The aim of our present study is to support peptide vaccination
approaches in cancer therapy by modeling the specific tumor-
immune interaction in a realistic fashion. For that purpose, we
integrated a previously published model of the tumor-immune
interplay [3] with a detailed description of the immune receptor-
ligand interactions based on structural and sequence information.
To our knowledge, this is the first approach simulating peptide
vaccination in cancer treatment that takes the peptide sequence
into account explicitly. An analogical approach designed for
generic infections has been described by Rapin et al. [4].
Rule-Based Modeling for Simulating the Immune System
Rule-based models are composed of discrete agents identifiable
within a spatial environment. The agents interact, move and
change their state according to behavioral rules in discrete time
steps.
One of the first approaches to simulating the immune system
using a cellular automaton was introduced in 1992 by Celada and
Seiden [5]. Their cellular automaton called ImmSim used very
simple rules but was able to reproduce several phenomena in
immunology, e.g. clonal expansion of B- and T-cells after
stimulation or the different time-lines of the first and second
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immunization. To account for specificity of the immune receptors,
they developed a representation in the form of bit-strings that had
to be complementary to favor an interaction between the immune
cells [6]. Within the model, they examined optimal ranges to
induce a sufficient immune response for some generic parameters
such as the number of major histocompatibility complexes
(MHCs) per individual or the number of self-peptides compared
to the whole diversity of protein sequences. The ImmSim model
has been extended and improved by several research groups (see
below); the present study itself is based on an implementation of
the Celada-Seiden ImmSim automaton.
Since 1992 the agent-based modeling community in theoretical
biology has grown. Apart from ImmSim, other rule-based immune
simulations have recently been developed which are briefly
reviewed here.
The Basic Immune Simulator aims at understanding the
interplay between the innate and the adaptive immune response
[7]. It is an agent-based model composed of three virtual spaces,
the parenchymal tissue, the secondary lymph node and the
lymphatic/humoral circulation. The immune response to a
localized viral infection is simulated, during which an immunity
gain or loss or a hyper-response might occur. The Basic Immune
Simulator was updated in 2010, now including new cell types and
enhanced behavioral rules [8]. Using the new version, a network
analysis was applied defining the cell types as nodes and their
interaction as edges.
SIMMUNE is more a modeling environment than a model of a
certain phenomenon [9]. Its purpose is to investigate how context
adaptive behavior might emerge from local cell-cell and cell-
molecule interactions. The model is composed of a cellular
automaton on a molecular level. Molecules can be defined that
interact according to the behavior they get equipped with. These
entities move within a discrete lattice, which can be subdivided
into different compartments. Since it takes a generic approach to
the modeling of cell biology, SIMMUNE is able to simulate a wide
area of signal cascades, not only those related to immunology.
SIMISYS is focused on the different stages of bacterial infection
[10]. The model is based on a cellular automaton and composed
of two different grids representing a blood vessel and a lymph
node. By means of the simulation, the authors want to learn more
about the interplay between the innate and adaptive immune
system.
Another rule-based study is the tumor-immune model by Mallet
and De Pillis [11]. They use a hybrid form of a cellular automaton
with partial differential equations. The purpose of this model is to
examine the effects of cytotoxic lymphocytes and natural killer
cells in the early stages of tumor growth under limited nutrient
supply.
The ImmSim model has also been enlarged, refined and applied
to a variety of phenomena. Castiglione et al. translated ImmSim to
ANSI C language and applied their refined model, C-ImmSim, to
several immunological phenomena, such as Epstein-Barr virus
infection [12], TH1/2 differentiation [13], HIV-infection [14] and
immune therapy of cancer [3]. C-ImmSim applied to cancer
simulates a solid tumor under immune therapy, including all main
mechanisms of the humoral and cellular adaptive immune
response. Lollini et al. used the architecture of C-ImmSim to
build SimTriplex, a model for HER2/neu transgenic mice treated
with the Triplex cell vaccine [15]. This model was extended and
applied to lung cancer metastasis in MetastaSim, which is a hybrid
agent-based/differential equation model [16].
For our research interest of studying peptide vaccination in
cancer treatment, the model C-ImmSim was the most suitable.
Indeed it provides all the important behavioral rules for immune
and cancer cells. The only major drawback of C-ImmSim is that
the immune receptors are modeled as bit-strings, having no direct
translation to amino acid sequences. Therefore, we decided to
extend C-ImmSim, producing a sequence-based version, Vac-
cImm, where all calculations depend on the amino acid sequence
of immune receptors, MHCs and antigens. In VaccImm,
experimental and clinical data of cancer targets, expression data
or MHC-genotypes are directly integrated into the model and the
simulation predicts the success of peptide vaccination taking the
amino acid sequence into account.
In order to understand the architecture of the model, C-
ImmSim is described in more detail in the next chapter.
Afterwards, the adoption of amino acid sequences in place of
bit-strings is discussed.
C-ImmSim
Our present model VaccImm is based on C-ImmSim [3], an
agent-based model written in ANSI C language. C-ImmSim is
composed of a Cartesian 3D lattice that contains cancer cells and
several types of immune-cells moving from one lattice point to
another in discrete time steps corresponding to 8 hours of real life.
The different types of immune cells can be classified as helper T-
cells (TH), cytotoxic T-cells (TC), B-cells, macrophages and
dendritic cells (DCs). In addition, the model includes different
classes of molecules comprising antibodies, antigens, Interleukin-2
(IL-2) and a danger signal that represents a general activator signal
for macrophages. These cells and molecules can interact according
to behavioral rules simulating the phenomena of an adaptive
immune response against cancer.
The lymph node close to the tumor is modeled explicitly by the
lattice that contains all cell types and molecules. In contrast, the
thymus selection is simulated implicitly, as all T-cells are probed
for their reactivity against MHC and self-peptides in positive and
negative selection before being introduced into the simulation.
All specific interactions of the adaptive immune response
depend on the complementarity of bit-strings in C-ImmSim. To
be more explicit, each immune cell receptor, MHC, antigen or
MHC-presented peptide is represented by a string composed of
zeros and ones, and whenever an immune receptor meets a
possible ligand, the complementarity of the bit-strings defines their
interaction probability. Whereas this way of representing the
molecular specificity is very generic and computationally easy, it is
very distant from real protein-protein interactions. The develop-
ment of a sequence-based definition of molecules is therefore an
important step toward the generation of more realistic models.
From Bit-Strings to Amino Acids
Rapin et al. have extended C-ImmSim to a sequence-based
version for simulating generic infectious diseases [4]. In contrast,
our extension, VaccImm, is focused on peptide vaccination in
cancer therapy and therefore has to fulfill several different needs.
To turn the bit-string model into a sequence-based model,
amino acid sequences need to be introduced for all specific
interactions between an immune receptor and a ligand. In
addition, in C-ImmSim the interaction strength is based on the
complementarity of bit-strings. In VaccImm, the interaction
probabilities dependent on amino acid sequence had to be
developed. Rapin et al. used the Miyazawa-Jernigan potential [17]
for that purpose. In the present work we demonstrate that this
approach does not clearly differentiate observed immune receptor-
ligand complexes from random complexes. For that reason, we
developed new interaction potentials specific to B-cell and T-cell
receptors that are able to clearly differentiate experimentally
observed from random complexes.
Immune-Specific Interaction Potentials for VaccImm
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Results
Development of an Interaction Potential for Immune
Receptor-Ligand Binding
An essential step in the adaptive immune response is the
recognition of a target cell by the immune cell mediated by the
immune receptor binding to its matching ligand. Both the
interaction of a T-cell receptor with a peptide-MHC complex
and a B-cell receptor with an antigen are very complex in nature
and still a matter of research [18,19]. Therefore, it is desirable to
have a universal function differentiating binding from non-binding
immune complexes.
In the present study, we develop a separate empirical pair-wise
interaction potential (IP) between the immune receptor and its
ligand for both the B-cell and the T-cell receptors. The IP is based
on an analysis of crystal structures from the Protein Data Bank
[20] using a similar method to that used by von Eichborn et al.
[21]. We compared the amino acid pairs within the interface of
observed crystal structures of immune receptor complexes to those
of random structures built to represent non-binding receptor
ligand pairs. From this calculation, we gained an IP specific for the
type of immune receptor-ligand-complex; IPT for T-cell receptors
and IPB for B-cell receptors (Fig. 1 and Fig. S1).
Before the analysis, structures were separated into training
(90%) and validation (10%) sets and then all complexes were
scored using IPT or IPB. The scores of training and validation sets
of the crystal and artificial structures were compared to scores that
were gained using the well known Miyazawa-Jernigan potential
[17], as Rapin et al. [4] used the Miyazawa-Jernigan potential to
score the immune receptor-ligand interaction. Our analysis shows
that for the peptide/MHC-TCR interaction the Miyazawa-
Jernigan potential is not able to differentiate between crystal and
artificial structures, while the sets can be clearly differentiated
using IPT (Fig. 2A). The area under curve (AUC) was calculated
with the Mann-Whitney test for the structures scored with IPT
yielding an AUC of 0.93 and a P-value below 0.01, so the
differentiation is highly significant.
For the BCR-antigen interaction, the Miyazawa-Jernigan
potential again does not differentiate between the crystal and the
artificial structures while IPB does (Fig. 2B). As the standard
deviation is very large when using IPB, we looked for any
characteristics of the structures to explain this phenomenon. We
found that the standard deviation can be considerably decreased if
the data sets are subdivided into sets with high and low glycine
frequencies within the antigen interface (Fig. 2C+D and Fig.
S2,S3). The limit was set at 6.9% glycine within the interface of the
antigen, as this is the frequency of glycine on protein surfaces. The
separation resulted in two data sets of nearly equal size. The
Mann-Whitney test yields an AUC of 0.93 for the high glycine
data set (IPB high) and 0.88 for the low glycine data set (IPB low),
while the P-value is below 0.01 for both. The reason for this
difference in high and low glycine content in the interface of an
antigen might be that the higher glycine content allows sharper
turns in the backbone and that could lead to a slightly different
mechanism of recognition by antibodies.
Application of the Interaction Potential in VaccImm
The newly developed IP was applied to the agent-based
simulation VaccImm, an extension of C-ImmSim [3], along with
approved prediction methods for MHC-peptide binding (see
Materials and Methods).
VaccImm accounts for the most important immune cell
populations in their different activation states. In this section, we
analyze these output-curves of the cell counts over time. Figure 3
depicts example curves of cell counts resulting from a successful
(right panel) and a failing (left panel) peptide vaccination therapy.
The difference between the two simulations is that the peptides of
the successful treatment were emulsified in adjuvant while the
peptides of the failed treatment were not. To initiate or boost the
immune response, adjuvant is often added for immunization [22].
Cancer epitopes are naturally of low immunogenicity as they result
from the body’s own proteins that are usually not recognized as
foreign.
Without adjuvant, the cancer cells double within one year
(Fig. 3A), while a successful treatment is able to eradicate the
tumor within less than four months (Fig. 3B). In successful immune
therapy, matching T-cell and B-cell receptors recognize the
antigen and TC-cells, TH-cells and B-cells get activated and
replicate, as seen in Figure 3. In contrast, peptide vaccination
without adjuvant is not able to activate TH-cells, TC-cells nor B-
cells for proliferation. Also the antigen presenting cells (APCs)
behave differently in the two settings. In both cases, DCs present
Figure 1. Interaction Potential IPT for MHC-Peptide/TCR Complexes. A: The newly developed interaction potential IPT for MHC-peptide/TCR
complexes. B: Color code and color frequency for interaction potential map.
doi:10.1371/journal.pone.0023257.g001
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peptides on their MHC I and MHC II, but without a stimulating
signal from the adjuvant this leads to anergy rather than to
activation of the T-cells. Macrophages are not recruited to present
peptides on their MHC II without adjuvant stimulation. In
successful treatment, presentation of both APC types on MHC
peaks when the antigen is injected but cell counts decrease
immediately afterwards because activated TC-cells kill the APC.
Impact of IPT on the Simulation with VaccImm
The most important step of the immune response against a
tumor is the recognition of a cancer epitope on MHC I by TC-
cells that will result in the lysis of tumor cells under activating
conditions. However, the bottleneck of cancer immunotherapy is
that most of the TC-cells that could possibly recognize the cancer
cells are eliminated in the thymus as they are reactive against self-
peptides. If a matching TC-cell survives thymus selection, lowering
of the tumor burden by the TC-cell clone depends on several other
factors e.g. the MHC-binding properties of the cancer epitope, the
way of antigen encounter by the TC-cell, its spatial environment
and the cytokine interplay. To analyze the impact of IPT and
thymus selection on the simulation, we compared their calculated
reactiveness.
Different antigens were evaluated for their score using IPT and
the T-cell reactivity they induced in the agent-based model
simulation. For that purpose, a set of about 15,000 TCR sequences
was randomly generated. In the first step, the antigens were sorted
by the highest IPT- score they gained when probed against the
whole TCR set (Fig. 4A). In the second step, all TCRs that would
not survive thymus selection, because of their complementarity to
self peptides, were eliminated and the antigens were scored again
with the reduced TCR set (Fig. 4B). In the third step, the entire
simulation was executed for all the antigens using VaccImm
(Fig. 4C). The reactiveness against cancer cells was defined as the
reduction of tumor size compared to unlimited growth, with 100%
reactiveness leading to complete tumor eradication.
In thymus selection, strongly self-reactive TC-cells are eliminated,
that is why several scores are lowered after thymus selection
(Fig. 4A+B). Nevertheless, the same overall trend was observed for
stronger and weaker immunogenic antigens. In the simulation, only
very few antigens are able to induce a sufficient immune response to
reduce or eradicate the tumor (Fig. 4C). Antigens having a low score
from IPT are not recognized by TC-cells because of their low
interaction probability. However, some antigens with high interaction
probabilities calculated from IPT are also not able to induce a
Figure 2. Evaluation of the Miyazawa Jernigan Potential and the Newly Developed Potentials IPT, IPB, IPB high and IPB low.Mean scores
of MHC/peptide-TCR crystal and random structures for training (90% of structures) and validation set (10% of structures) are depicted. Scores
observed using the newly developed interaction potentials and the Miyazawa-Jernigan interaction potential [17] are compared. A: Scores of MHC/
peptide-TCR complexes using IPT. B: Scores of antibody/antigen complexes (all) using IPB. C: Scores of antibody/antigen complexes with antigens of
high glycine frequency (.6.9%) within the interface using IPB high. D: antibody/antigen complexes with antigens of low glycine frequency (,6.9%)
within the interface using IPB low. * indicates P-value of crystal and random set below 0.01 using Mann-Whitney test. M-J-potential: Miyazawa-Jernigan
potential.
doi:10.1371/journal.pone.0023257.g002
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Figure 4. Comparison of IPT, Thymus Selection and Simulation. Scores for different antigens using IPT are compared with (A) a random
sample of about 15,000 TCRs , (B) all TCRs from the set that survived the thymus selection and (C) with the reactiveness against cancer cells in the
simulation with VaccImm. The antigens in all three diagrams are sorted by their IPT-score including all TCRs. Antigens inducing an immune response
against the tumor, are marked with *. Simulation data were obtained from 100 simulations per column. The MHC-genotype is HLA_A02/HLA_DRB3.
For all experiments one hundred initial cancer cells were simulated within 5 ml of blood that were treated with peptide injections starting at time
point zero and being repeated five times at an interval of 28 days. The antigens were chosen from over-expression data in prostate tumors. One MHC
I-binding peptide and one MHC II-binding peptide were injected.
doi:10.1371/journal.pone.0023257.g004
Figure 3. Peptide Vaccination With and Without Adjuvant. Cell counts are depicted for cancer cells (A/B), cytotoxic T-cells (C/D), helper T-cells
(E/F), B-cells (G/H), dendritic cells (I/J) and macrophages (K/L) over one year of simulated time. One time step equals 8 hours. Left panel: No adjuvant
was added; right panel: Adjuvant was included. For both experiments one hundred initial cancer cells were simulated within 5 ml of blood that were
treated with peptide injections starting at time point zero and being repeated five times at an interval of 28 days. The MHC-genotype of this virtual
individual is HLA_A80/HLA_B56/HLA_DQA2_DQB2/HLA_DRB3. The antigen A2SUH6_HUMAN (Survivin variant 3 alpha) was chosen from over-
expression data in prostate tumors. Two MHC I-binding peptides and two MHC II-binding peptides were injected.
doi:10.1371/journal.pone.0023257.g003
Immune-Specific Interaction Potentials for VaccImm
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sufficient immune response. This result underlines that the complete
immune cell and signal molecule interplay needs to be investigated for
understanding the tumor-immune-interaction.
In the next section, we analyze the failing antigen treatments in
more detail.
Reasons for Failures in Treatment
In order to better understand the reasons why the immune
system failed to successfully fight the tumor for most of the antigen
injections, we took a closer look at the immune cell populations
(Fig. 5). A successful treatment was defined as a simulation with a
smaller tumor size after one year of simulated time with respect to
the beginning of treatment.
Interestingly, we found that the resulting patterns can be
separated into two groups: In the first group, a sufficient immune
response was induced in less than 50% of the simulations (frequent
failures, Fig. 5a) and in the second group in more than 50% (rare
failures, Fig. 5b). In both groups, peptide presentation on MHC I
and II by DCs and macrophages was successful in 75% to 100% of
the simulations. Consequently, this part of the immune response
was not the main bottleneck in the treatment. In the frequent
failures, no active TC-cells and almost no active TH-cells were
observed. For the rare failures, active TC-cells were observed in
more than 80% of the failing simulations. We did take a closer
look at these TC-cell populations, searching for a reason why they
were not able to eradicate the tumor. We found that these TC-cell
populations were either very small (composed of only one or two
cells) or started dividing at a later stage of the simulation such that
the tumor size could not be decreased before the end of the
simulation (data not shown).
These observations indicate that the rare failures would occur with
an even lower frequency if the simulations were carried out over a
longer time period. In contrast, the frequent failures are prone to failing
to induce an immune response either because their antigens are too
closely related to self-peptides or because the TC-cells did not
encounter the antigen in a sufficiently activating environment.
Simulation Run Time and Error Propagation from the
Interaction Potential
VaccImm is able to simulate up to one million initial cancer
cells treated with a maximum of ten peptides. One run of the
simulation takes from several seconds to a few minutes on a single
core of a 3 GHz Intel Core 2 Duo CPU depending on the input
parameters chosen.
Before starting the simulation, peptide sequences binding to
MHC I and MHC II are predicted within a few seconds. The
VaccImm simulation itself can be divided into two parts, thymus
selection of initial population of T lymphocytes and spatial
dynamics within the agent-based model accounting for the whole
immune response. Having a simulation with standard configura-
tion (see Table 1), the two parts require about the same amount of
CPU time. In general, however, while the time for thymus
selection increases with the number of self-peptides and the
number of different MHC-alleles, the time for the agent-based
simulation increases with cell numbers, simulated time and
volume. Some benchmark experiments with their simulation times
are given in Table 1.
To investigate the error propagation from the IP to the
simulation, an example was chosen where the tumor is almost
eradicated. The interaction probability calculated using IPT, IPB
high and IPB low was increased or decreased in a stepwise manner
and the impact on the final number of cancer cells and the time it
takes to reduce the cancer cell number compared to the initial
tumor size was analyzed (Fig. 6). Increasing the interaction
probability led to a gradual decrease in the time to reduce the
tumor size while the tumor was almost or completely eradicated
with an increase in the interaction probability of 10% and more.
Decreasing the interaction probability increased the time to reduce
the tumor and the relative number of cancer cells at the end of the
simulation. At a 15% decrease of the interaction probability, the
mean number of cancer cells was not reduced compared to the
beginning of the simulation. Decreasing the interaction probability
by 20% or more leads to tumor reduction in less than 50% of the
simulations.
From these results we can deduce that a bias in IPT, IPB high and
IPB low will affect the results of the simulation. A qualitative
difference in the outcome, as having or not having an induction of
the immune response, will probably occur from a bias larger than
10–15%.
Discussion
In this work, we developed new IPs between an immune
receptor and its ligand from a statistical analysis of crystal
Figure 5. Reasons for Failures in Treatment. The propensity to obtain certain activation states of the immune cell populations is depicted.
Experiments are grouped into frequent failures (A) that induce a sufficient immune response in less than 50% of the simulations and rare failures (B)
with more than 50% sufficient responses. Abbreviations: TC active: active cytotoxic T-cells. TH active: active helper T-cells. DC presI/DC presII:
dendritic cells presenting peptides on MHC I/MHC II. MA presII: macrophages presenting peptides on MHC II.
doi:10.1371/journal.pone.0023257.g005
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structures for B-cell and T-cell receptors. It was shown that the
newly developed IPs are able to differentiate naturally observed
from randomly generated immune complexes, in contrast to the
Miyazawa-Jernigan potential [17]. We believe that our empirically
developed potentials account for specific properties of the
respective immune receptor interactions, that are not included in
general potentials like the Miyazawa-Jernigan potential.
In the second step, the newly developed IPs were applied to the
agent-based model VaccImm, an extension of C-ImmSim [3].
There is one other agent-based model that includes the amino acid
sequence in calculation; the model of Rapin et al. [4] simulates the
immune response against infections and was developed indepen-
dently from VaccImm. While Rapin et al. took a more general
approach to infectious diseases; we focused on the specific needs of
peptide vaccination in cancer therapy.
Prediction methods for complex protein-protein interactions,
such as our newly developed IPs, always have a limited accuracy.
Therefore, we investigated what impact a systematic error in the
IPs would have on the VaccImm simulation. As demonstrated, a
bias in the IPs will surely affect the simulation, but qualitative
changes in the outcome are not expected as long as the bias in the
interaction prediction stays below 10%.
In contrast to the former versions of C-ImmSim, and similarly
to the new published version [4], VaccImm predicts reactivity of
the immune system against real amino acid sequences of any
injected peptide. The model includes several core phenomena of
the immune system, e.g., the humoral and cellular branch, clonal
expansion of single immune cells, thymus selection of T-cells and
spatial interactions of autonomous cells with distinct specificity.
Still, some properties of the immune-cancer interplay might be
underrepresented in the current version of the model and we are
planning to extend VaccImm in that direction. The most
important features we are planning to include in the future are
the different types of cytokines, the influence of regulatory T-cells
(Tregs) and the mutation of cancer cell epitopes.
Cytokines have an essential role in facilitating communication
between immune cells, most of them acting within short ranges
[23]. Thus far, only IL-2 and a general danger signal are included
in the simulation, but agent-based models are particularly tailored
Table 1. Computational Cost of the Simulation.
Configuration
Computational
Time [s]
Standard* 21
Initial tumor size [cells]: 10 000 33
Initial tumor size [cells]: 100 000 129
Initial tumor size [cells]: 1 000 000 855
Simulated Space [ml]: 10 82
Simulated Space [ml]: 20 165
Simulated Space [ml]: 20, Initial tumor size [cells]: 100 000 250
2 MHC-I binding peptides, 2 MHC-II binding peptides 40
3 MHC-I binding peptides, 3 MHC-II binding peptides 73
4 MHC-I binding peptides, 4 MHC-II binding peptides 100
5 MHC-I binding peptides, 5 MHC-II binding peptides 117
2 MHC-I alleles, 2 MHC-II alleles 31
3 MHC-I alleles, 3 MHC-II alleles 57
6 MHC-I alleles, 6 MHC-II alleles 45
2190 time steps 25
4380 time steps 34
*The standard configuration for the simulations is: Uniprot-ID 2B1D_HUMAN, 1
MHC-I allele, 1 MHC-II allele, 1 MHC-I binding peptide, 1 MHC-II binding peptide,
5 ml simulated space, 1095 time steps, 100 cancer cells as initial tumor size. All
changes to this configuration are mentioned in the table.
doi:10.1371/journal.pone.0023257.t001
Figure 6. Error Propagation from IP to Simulation. The relative number of cancer cells after one year of treatment compared to the tumor size
at the beginning of the simulation is depicted (red bars) along with the average number of time steps needed to reduce the tumor size (green bars).
All interaction probabilities in the simulation calculated with IP were multiplied with the bias in IP shown on the y-axis. Data were obtained from 100
simulations per column. The MHC-genotype is HLA_A02/HLA_DRB1-1. For all experiments one hundred initial cancer cells were simulated within 5 ml
of blood that were treated with peptide injections starting at time point zero and being repeated five times at an interval of 28 days. The antigen
B7Z8B0_HUMAN was chosen from over-expression data in prostate tumors. One MHC I-binding peptide and one MHC II-binding peptide were
injected.
doi:10.1371/journal.pone.0023257.g006
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to take into account local effects of molecules in a spatial
environment. Consequently, we are planning to include a more
detailed representation of cytokines in the model in the future.
Examples for important cytokines in the cancer-immune interplay
to be included soon are the transforming growth factor-b [24] or
interferon-c [25].
Tregs are an immune cell population suppressing the immune
response, presumably with the main function to prevent
autoimmune diseases [26]. Their immunosuppressive effect
hinders the immune response against cancer [27]. Therefore,
our plan is to include this cell type in the next version of VaccImm.
Our current model does not account for mutation or changes in
gene expression of the tumor. The genome of a tumor is often
unstable and many different mutations or gene rearrangements
result in a huge diversity of tumor cells that do not present the
same epitopes on their MHCs. It is frequently observed,
particularly under treatment, that some tumor cells change their
behavior or their expression pattern, thereby circumventing
eradication; a phenomenon called tumor escape [28]. For this
purpose, we plan to include tumor epitope mutation and changes
in the antigen expression levels.
The present model is a first step towards in silico experiments
predicting T-cell reactivity taking into account the amino acid
sequence. Expanding knowledge in tumor immunology will help
to further improve our model. As VaccImm is very flexible and its
architecture is separated into different modules, it can be easily
extended or refined with new experimental data.
Materials and Methods
Peptide Binding to MHC Complexes
The first step necessary for T-cell recognition is the processing
of a protein to a peptide and its presentation on a MHC complex
by the target cell. This process has been evaluated in great detail
by several research groups. It has been found that key residues
exist at distinct places within the peptide that are most important
for binding to the MHC [29]. From the accumulated MHC
binding and elution data, several methods have been generated to
predict which part of the protein sequence will be presented by a
certain MHC. For simulation, we used two well-known position-
specific scoring matrices to predict peptide-MHC binding, namely
smmpmbec (http://tools.immuneepitope.org) for MHC I binding
and arb [30] for MHC II binding.
Development of an Interaction Potential for Immune
Receptor-Ligand Binding
A separate empirical pairwise interaction potential between the
immune receptor and its ligand was developed for both the B-
and T-cell receptor, based on crystal structures from the Protein
Data Bank [20] using a similar method to that used by von
Eichborn et al. [21]. A statistical analysis was drawn from 237
antibody-antigen and 33 MHC-TCR non-redundant crystal
structures. Interacting amino acid pairs between receptor and
ligand were defined as all residues having no more than 8 A˚
distance between their Ca atoms. We compared the observed
crystal structures to random structures built to represent non-
binding receptor ligand pairs. To generate the random structures,
the peptide sequences of the MHC-peptide complex or the
antigen were replaced by random sequences with the same amino
acid distribution that was observed on general protein surfaces.
The number of interacting pairs was counted for both the crystal
and the random structures and the numbers were subtracted
using the formula:
M(x, y)~Ccrystall(x, y){Crandom(x, y) Vx, y[AA
where M is the interaction potential scoring matrix and Ccrystal
and Crandom are the counts for crystal and random structures,
respectively. From this calculation, we gained an interaction
potential (IP) specific for the type of immune receptor-ligand-
complex; IPT for T-cell receptors and IPB for B-cell receptors.
Within IPT and IPB, positive values represent an increased
likelihood of observing the corresponding amino acid pair in the
interface of the complex, while negative values represent a
decreased likelihood. IPT and IPB were normalized to a
maximum value of 1.0 and then used to score the crystal and
artificial structures for validation.
Application of the Interaction Potential to the Simulation
Whenever an active T-cell meets an APC presenting a peptide
on a matching MHC type, their interaction probability is
calculated using IPT. To define which residues of the immune
receptor and the ligand are in contact with each other, we created
contact matrices from crystal structures analogously to the work of
Rapin [4]. Again, the interacting amino acid pairs between
receptor and ligand were defined as all residues having at most 8 A˚
distance between their Ca atoms. For each crystal structure, a
matrix composed of ones and zeros representing interacting and
non-interacting residues was created. In a next step the interaction
probability was calculated as the sum of the IPT matrix values for
all interacting residues that is normalized by the number of
interactions.
As the number of MHCs with known structure is limited, MHC
sequences not having been crystallized were mapped to the closest
related MHC structures for the definition of the contact residues.
Contact matrices were built from MHC-peptide-TCR complexes
containing HLA_A02 (pdb-ID: 1OGA), HLA_B08 (1MI5),
HLA_B35 (3MV7), HLA_B44 (3DXA), and HLA_DRB1-4
(1J8H). For the interaction between a BCR or an antibody and
its antigen, we used one high-resolution structure of an antibody
binding to a peptide (2B1H) to create the contact matrix, as the
injected antigens are peptides and their tertiary structure can
probably be neglected.
Steps of the Simulation
Starting the simulation, the different behaviors and movements
of the cells are executed in discrete time steps. For the purpose of
modeling peptide vaccination to treat cancer with VaccImm, the
timeline of observed phenomena is as follows:
1. The peptides are injected emulsified in adjuvant. The adjuvant
is modeled as a danger signal activating macrophages.
2. APCs take up the peptides by phagocytosis. In the case of
macrophages and DCs, phagocytosis is unspecific, while B-cells
have to recognize the antigen for ingestion. The probability of
recognition is calculated using the B-cell contact matrix and
IPB high or IPB low depending on the antigen.
3. Peptides are processed and presented by the APCs. The
probability of presenting a certain peptide by a specific MHC is
calculated using the position-specific scoring matrices described
above.
4. The peptides presented on MHC I and MHC II can be
recognized by TC- and TH-cells, respectively. The probability
for recognition is calculated using IPT together with the contact
matrix for the respective MHC. Reacting T-cells will be
activated to duplicate and create memory cells.
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23257
5. The humoral and the cytotoxic immune response begin.
Activated TC-cells might recognize the cancer cells, while the
probability of interaction is calculated again via IPT and the
respective contact matrix. Successful interactions between TC-
cells and cancer cells will kill the cancer cells and therefore the
tumor will be eliminated. B-cells stimulated by TH-cells start
duplicating into memory cells and antibody-producing plasma
cells. Plasma cells secrete antibodies that clear the antigen.
This model is quite generic and flexible and captures the main
mechanisms in the tumor-immune interaction. As an output of the
model, cell lines and their respective activation states can be
followed over time.
Input Data
For VaccImm, all sequence-based input parameters needed to
be changed with respect to C-ImmSim. Within the present
analysis, we focus on urological tumors of kidney and prostate, but
the program is very general and able to simulate any solid tumor.
As input, the model needs the amino acid sequences of the
cancerous proteins, the MHC alleles, and the self-peptides used in
thymus selection.
Cancerous proteins were selected based on expression data from
patients suffering from prostate or kidney tumors. [31]. Any gene
that is over-expressed at least 2 times in the analyzed cancerous
tissue with respect to healthy control tissue was chosen as a cancer
target. The respective protein sequences were collected from the
UniProt. [32]. Peptides presented on MHC I or MHC II
originating from the protein sequences were predicted using
prediction algorithms (consensus [33] for MHC I, smm_align [34] for
MHC II) from the Immune Epitope Database [35]. These
predicted peptides are presented by the MHCs in the simulation.
The same peptide sequences are used for injection in immune
therapy within the simulation. As short peptides usually do not fold
into complex secondary structures, the injected peptides are used
directly as epitopes for recognition by B-cells and antibodies.
One part of the simulation is the selection of T-cells within the
thymus. If any T-cell receptor is strongly reactive to self-peptides,
the T-cell will be eliminated. To define the self-peptides, we
downloaded all peptide sequences eluted or known to bind to
MHC I or MHC II from the IEDB [35]. To decrease the number
of self-peptides and therefore increase the speed of the simulation,
we used only the 50 self-peptide sequences most similar to each
injected peptide. All other self-peptide sequences having a lower
similarity will not interfere with the injected peptides and thus are
neglected.
The MHC sequences for all different alleles were downloaded
from the UniProt [32], 61 for MHC I and 20 for MHC II. All
TCR and BCR sequences were generated at random when the
respective cell was introduced into the simulation.
Any other parameter not pertaining to the amino acid sequence
implementation are left unchanged with respect to C-ImmSim [3].
Supporting Information
Figure S1 Interaction Potential IPB for All Antibody/
Antigen Complexes. A: The newly developed interaction
potential IPB for all antibody/antigen complexes. B: Color code
and color frequency for interaction potential map.
(TIFF)
Figure S2 Interaction Potential IPB high for Antibody/
Antigen Complexes, High Glycine Frequency. A: The
newly developed interaction potential IPB high for antibody/
antigen complexes with antigens of high glycine frequency
(.6.9%) within the interface. B: Color code and color frequency
for interaction potential map.
(TIFF)
Figure S3 Interaction Potential IPB low for Antibody/
Antigen Complexes, Low Glycine Frequency. A: The newly
developed interaction potential IPB low for antibody/antigen
complexes with antigens of low glycine frequency (,6.9%) within
the interface. B: Color code and color frequency for interaction
potential map.
(TIFF)
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